Delivery Order SPE2DR25D1041-SPE2DR26FHP8D
- Not listed
- The Defense Logistics Agency (DLA) awarded a $11,073.06 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ondansetron HCl 4 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 10, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $5,996.73 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was executed on August 14, 2025, with an ultimate completion date of August 15, 2025. The contract does not include a set-aside designation. Performance will be fulfilled from AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 500 units, with a ceiling value of $5,252.73. This is a firm fixed price delivery order with an ultimate completion date of August 8, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500 count) under a firm fixed-price contract valued at $23,815.66. The award, made on September 15, 2025, is a competitive delivery order with no set-aside designation and an ultimate completion date of September 16, 2025. Performance will be executed from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Ondansetron HCL 4 mg tablets (500 count) valued at $6,599.70. This is a firm fixed-price delivery order with an ultimate completion date of August 14, 2025, and represents a non-competitive set-aside award. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,931.30 to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Ondansetron HCl 4 mg tablets (500 count). The contract, which is of the firm fixed-price delivery order type with no set-aside designation, represents a competitive award to the pharmaceutical distributor. Performance of this order is scheduled for completion by July 15, 2025, and will be executed at the awardee's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $3,707.67 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 8 mg tablets (30-count packaging). This contract, awarded on August 19, 2025, with a completion date of August 20, 2025, utilizes firm fixed pricing and was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ondansetron HCL 4 mg tablets (500 tablets) with a ceiling value of $5,367.10. This is a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, and represents a non-set-aside competitive award. The product will be supplied from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ondansetron HCl 4 mg tablets (30-count packaging) with a ceiling value of $25,134.02. This firm fixed-price delivery order, which is not set-aside, represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The product will be performed and delivered from...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,186.32 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500 count) on September 2, 2025, with completion scheduled for September 3, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed under AmerisourceBergen's broader indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical supply will be delivered to the...
- SPE2DR25D1041Indefinite Delivery Contract
- SPE2DR25D1041-SPE2DR26FHP8DDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,018.74 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (30-count packaging). This competitively awarded, firm fixed-price contract with no set-aside designation was executed on October 24, 2025, with an ultimate completion date of October 27, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 through December 2026. This comprehensive pharmaceutical prime vendor contract enables AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare systems globally. The ondansetron delivery under this order supports the Defense Health Agency and other federal healthcare systems' antiemetic medication needs, reflecting AmerisourceBergen's critical role as a major pharmaceutical distributor for defense medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.0k | 10/24/25 |